Cardiac AI: Investing in Preclinical Scale, Not Zombie Startups

Preclinical cardiovascular risk detection, a frontier promising to avert catastrophic health events, is rapidly becoming a winner-take-all market. The immense data requirements and intricate clinical integration necessary for meaningful impact mean that only platforms capable of achieving significant scale will ultimately succeed and endure. For investors, understanding the foundational elements that enable this scale is paramount to identifying the market leaders and avoiding ventures destined to become zombie companies.

The Unforgiving Landscape of Preclinical Cardiovascular AI

The promise of AI in healthcare, particularly in identifying cardiovascular risks before they manifest acutely, is profound. Imagine a future where myocardial infarctions, strokes, and heart failure can be predicted with high accuracy years in advance, allowing for timely, preventative interventions. This vision, however, is not easily realized. Effective preclinical detection demands AI models trained on vast, diverse datasets encompassing genomic, imaging, clinical, and lifestyle information. Furthermore, these models must integrate seamlessly into complex healthcare workflows, generating actionable insights that clinicians can trust and act upon. The challenge is not merely technological; it is fundamentally about data acquisition, curation, and deployment at an unprecedented scale. Early-stage startups, often fueled by innovative algorithms or niche datasets, frequently struggle to bridge the chasm between promising proof-of-concept and enterprise-grade deployment. This is where the concept of a “data moat” becomes critical. Companies that can establish proprietary access to unique, longitudinal, and clinically relevant datasets gain an almost insurmountable competitive advantage, making it nearly impossible for new entrants to match their accuracy or regulatory traction.

Tempus AI: The Genomic Juggernaut in Precision Medicine

When considering scale as the ultimate moat, Tempus AI stands as a compelling exemplar, albeit with a broader precision medicine focus that inherently touches cardiovascular risk. Now a publicly traded company on NASDAQ (TEM), Tempus AI, with a market capitalization of $7.72 billion as of July 28, 2026, and having raised $3.06 billion in funding prior to its IPO, has strategically built one of the largest clinical and molecular datasets in the world. While not exclusively centered on cardiovascular disease, their approach to integrating genomic sequencing with clinical data provides a powerful platform for identifying predispositions to various conditions, including inherited cardiovascular diseases and pharmacogenomic insights relevant to cardiac medications. Tempus’s strategy is to create a comprehensive data ecosystem. They partner with health systems to sequence patient tumors and healthy tissues, often at no cost to the institution, in exchange for access to de-identified clinical data. This creates a powerful data flywheel: more data leads to better AI models, which in turn attract more partnerships and more data. This massive genomic database, reportedly encompassing millions of patient records and billions of data points Tempus AI genomic database scale report, allows them to develop AI-driven insights into disease progression, treatment response, and, crucially, risk stratification. For instance, identifying genetic markers associated with increased risk for cardiomyopathies or hypercholesterolemia falls squarely within their capabilities, moving towards preclinical detection through a genomic lens. Their scale in data acquisition and their deep integration into oncology workflows provide a robust foundation that could readily extend more explicitly into cardiovascular risk. While their primary focus has been cancer, the underlying infrastructure for data aggregation, AI model development, and clinical integration is directly transferable. Investors looking at preclinical cardiovascular risk should recognize that a company like Tempus, with its established data moat and enterprise contracts, represents a formidable force, capable of pivoting or expanding its AI applications into adjacent high-value areas.

Viz.ai: Acute Intervention as a Wedge for Preclinical Expansion

Viz.ai offers a different, yet equally compelling, demonstration of how scale in one critical area can serve as a wedge product for broader impact, including nascent preclinical detection capabilities. Viz.ai, which achieved a $1.2 billion valuation in 2022 and has raised $289.25 million across 10 funding rounds, initially focused on acute stroke detection and triage. Their core product uses AI to analyze medical images (CT scans, MRIs) for signs of large vessel occlusion (LVO) strokes, immediately alerting stroke teams and facilitating faster treatment. This rapid communication and workflow optimization have demonstrably improved patient outcomes in acute settings. Viz.ai’s success is rooted in its ability to deploy SaMD (Software as a Medical Device) that integrates directly into hospital PACS systems and leverages a mobile communication platform. They have secured 13 FDA clearances for their algorithms, demonstrating regulatory maturity and clinical validation FDA 510(k) database for Viz.ai clearances. These clearances include their AI-powered LVO stroke detection and notification, AI for pulmonary embolism detection, and more recently, algorithms for intracerebral hemorrhage (ICH Plus) and subdural hemorrhage (Subdural Plus). The key insight for investors is that Viz.ai’s extensive network of hospital contracts, built on the back of their acute stroke solution, provides an unparalleled distribution channel and a continuous stream of imaging data. This hospital network footprint is not just about acute care; it’s a strategic asset for future expansion into preclinical cardiovascular risk. Consider the data captured by Viz.ai’s platform: thousands of CT scans, many of which may incidentally reveal early signs of cardiovascular disease, such as coronary artery calcification or aortic aneurysms. Their established presence within radiology departments and emergency rooms positions them uniquely to develop and deploy AI algorithms that screen for these preclinical indicators. While their current focus is acute, the infrastructure for data collection, AI inference, and clinical alert dissemination is perfectly suited for a proactive, preclinical approach. Their recent expansion into pulmonary embolism detection further illustrates their capability to extend beyond their initial wedge product into broader cardiovascular applications.

Olive AI: A Cautionary Tale of Scale Without Product-Market Fit

To underscore the importance of scale intertwined with genuine product-market fit and a robust data strategy, we must examine the cautionary tale of Olive AI. Having raised $902 million from investors, including Tiger Global, and reaching a peak valuation of $4 billion, Olive AI aimed to revolutionize administrative tasks in healthcare using AI. Their ambition was to automate everything from prior authorizations to claims processing, promising massive cost savings for health systems. However, despite significant funding and a bold vision, Olive AI ultimately failed, leading to a complete shutdown on October 31, 2023. The post-mortems reveal several critical missteps Olive AI shutdown post-mortems. While they pursued scale aggressively, their products often lacked the deep clinical integration and demonstrable, consistent ROI that health systems demand. Administrative tasks, while seemingly amenable to automation, proved far more complex and nuanced than anticipated, often requiring bespoke solutions rather than a one-size-fits-all AI platform. Their AI models struggled with algorithmic drift due in part to the variability of administrative data across different health systems and the constant evolution of billing codes and regulations. Olive AI’s downfall highlights that simply throwing capital at a problem and acquiring customers does not guarantee success if the underlying AI solution doesn’t deliver tangible, repeatable value. Their attempts to build a data moat were undermined by the fragmented nature of administrative data and the difficulty in creating a truly generalizable AI product. For investors, Olive AI serves as a stark reminder that even substantial funding and a large addressable market are insufficient without a clear path to scalable, validated outcomes and a product that genuinely solves a critical, well-defined problem. The “scale is the ultimate moat” axiom only holds true when that scale is built upon a foundation of effective, validated technology and strong product-market fit, not just ambition.

Investor Takeaway: Betting on Data Flywheels and Distribution

The preclinical cardiovascular risk detection market is not a level playing field. It heavily favors companies that have already established significant data flywheels and robust distribution networks. Early-stage startups, while potentially innovative, face an uphill battle against the entrenched advantages of players like Tempus AI and Viz.ai. These incumbents possess:

• Proprietary Data Moats: Access to vast, unique datasets (genomic, imaging, clinical) that are difficult, if not impossible, for competitors to replicate. This is a critical component for training and validating high-performing AI models, especially for complex tasks like preclinical risk detection.
• Established Enterprise Contracts: Deep relationships with health systems, providing both a continuous source of real-world data and a direct channel for product deployment and scaling. These relationships often come with the trust and integration necessary for AI to move beyond pilot programs.
• Regulatory Maturity: A track record of securing FDA clearances (510(k) or De Novo), demonstrating their ability to navigate the complex regulatory landscape for SaMD and build trust with clinicians and payers.
• Clinical Validation: A history of publishing outcomes data, whether through real-world evidence (RWE) or clinical trials, proving the efficacy and utility of their AI solutions. For investors, the strategic imperative is clear: bet on companies that have already secured these foundational elements. Look for startups that are AI-native, meaning their core product and business model were built from inception around AI and data, rather than AI being a bolt-on acquisition. Scrutinize their QMS / ISO 13485 certifications and their adherence to GMLP (Good Machine Learning Practice) to ensure regulatory debt isn’t lurking in the data room. The path to public markets for these leading private AI health companies will be paved by their ability to leverage their existing scale to expand into new, high-value use cases like preclinical cardiovascular risk detection. It’s not just about who has the best algorithm today, but who has the infrastructure, data, and distribution to continuously improve and deploy algorithms that will define the future of preventative healthcare.
  

  Methodology Note

  This analysis is based on comprehensive analyst research, drawing upon publicly available information including the FDA 510(k) clearance database, corporate press releases, investor reports, industry publications detailing corporate partnerships and market share data, and post-mortems of relevant market failures. Insights into company valuations and funding rounds are derived from established financial reporting and venture capital databases. The assessment of competitive advantage centers on verifiable indicators of scale, regulatory achievement, and market penetration, rather than speculative projections.